Townson Sharon
Chief Scientific Officer
Townson Sharon has filed 5 SEC Form 4 filings (11 transaction rows) across 1 company, with disclosures dating back to 2026. 5 of those filings fall inside the rolling window. Most recent filing: Jul 7, 2026.
On the most recent filing, Townson Sharon is listed as Chief Scientific Officer at Monte Rosa Therapeutics, Inc. Inside the rolling window, Townson Sharon reported no open-market purchases and 5 open-market sales totaling $424K in GLUE. The largest disclosed transaction in the window is a sale of 6,000 GLUE shares on Jul 6, 2026, worth $140K.
Companies traded
Other insiders at GLUE
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$424K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Townson Sharon made?
Townson Sharon has filed 5 SEC Form 4 filings (11 transaction rows) across 1 company since 2026.
Which companies does Townson Sharon trade?
Townson Sharon has filed SEC Form 4 disclosures for 1 company, including GLUE.
When was Townson Sharon's most recent SEC Form 4 filing?
Townson Sharon's most recent SEC Form 4 filing on Tracefour is dated Jul 7, 2026.
What is Townson Sharon's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Townson Sharon is listed as Chief Scientific Officer.
What is Townson Sharon's total buy and sell value in the current window?
Inside the rolling retention window, Townson Sharon bought $0 and sold $424K based on SEC Form 4 filings.
What was Townson Sharon's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 6,000 GLUE shares on 2026-07-06, worth $140K, per SEC Form 4 filings.